LifeMD (NASDAQ:LFMD) Earns “Buy” Rating from HC Wainwright

LifeMD (NASDAQ:LFMD)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 67.60% from the company’s previous close.

LFMD has been the topic of several other research reports. B. Riley assumed coverage on LifeMD in a report on Friday, August 23rd. They set a “buy” rating and a $11.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 price objective on shares of LifeMD in a report on Friday, September 20th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, LifeMD presently has a consensus rating of “Buy” and a consensus target price of $12.00.

LifeMD Price Performance

Shares of NASDAQ:LFMD opened at $7.16 on Monday. LifeMD has a 1-year low of $3.99 and a 1-year high of $12.88. The firm has a market capitalization of $308.37 million, a PE ratio of -11.19 and a beta of 1.23. The business’s 50 day moving average is $4.91 and its 200-day moving average is $6.46. The company has a current ratio of 0.87, a quick ratio of 0.83 and a debt-to-equity ratio of 10.83.

Hedge Funds Weigh In On LifeMD

Several institutional investors have recently bought and sold shares of LFMD. Quest Partners LLC bought a new position in LifeMD in the 2nd quarter valued at $31,000. nVerses Capital LLC bought a new position in LifeMD in the 3rd quarter valued at $46,000. Intech Investment Management LLC bought a new position in LifeMD in the 3rd quarter valued at $54,000. CWM LLC bought a new position in LifeMD in the 3rd quarter valued at $59,000. Finally, SG Americas Securities LLC bought a new position in LifeMD in the 3rd quarter valued at $70,000. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.